PDCD1 and neoplasm: Currently, ICIs such as those encompassing programmed cell death protein 1 (PD‐1) inhibitors,129 cytotoxic T‐lymphocyte antigen 4 inhibitors130 and T‐cell immunoglobulin, and mucin domain 3 inhibitors,131, 132 have gradually established themselves as standard‐of‐care interventions across multiple tumour types.